SYHA-1813
- Generic Name
- SYHA-1813
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
Phase 2
Not yet recruiting
- Conditions
- Recurrent or Progressive High Grade Meningioma
- Interventions
- Drug: Investigator's Choice Treatment
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06739213
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 1
Not yet recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath